| Product: | Phosmin (calcium acetate), tablets |
| Indication: | Treatment for hyperphosphatemia in ESRD patients (Rx) |
| Status: | Preclinical |
Phosmin is a calcium-based phosphate binder for the control of serum phosphorus in patients with end-stage renal disease (ESRD).
Hyperphosphatemia in ESRD Patients
Hyperphosphatemia in patients with end-stage renal disease (ESRD) can lead to secondary hyperparathyroidism, renal osteodystrophy, soft tissue mineralization and the progression of renal failure – all of which significantly increase patient mortality and morbidity.
As such, phosphorus control is critical to the quality of care for dialysis patients.
Treatment with Phosphate Binders
The treatment of hyperphosphatemia usually involves dialysis in conjunction with dietary phosphate restrictions and intake of phosphate binders. Phosphate binders are generally classified as calcium-based and non-calcium-based drugs.
Calcium acetate is an intestinal, calcium-based phosphate binder that is roughly three times more effective than calcium carbonate in controlling serum phosphate. When taken with meals, calcium acetate binds with dietary phosphate to form insoluble calcium phosphate, which is subsequently excreted in the feces. By controlling phosphorus absorption from the gastrointestinal tract, calcium acetate controls the serum phosphorus level.
Patients with higher-than-normal serum calcium levels should be closely monitored and their dose adjusted to bring levels to normal. They can also consider CM139, which combines magnesium carbonate with calcium acetate to slow the calcification process. For those dialysis patients who are clinically hypercalcemic, with severe vascular and/or other soft tissue calcifications, FC818, is a novel non-calcium phosphate binding alternative.Phosmin
Phosmin is a calcium acetate product for binding phosphate in ESRD patients.
